1
|
De Almeida JPL, Martinho S, Campos G, Alves P, Rosa J, Ferreira M, Goncalves L. Predicting the long-termoutcome of patients admitted with acute heart failure to the emergency department using renal markers. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Renal dysfunction is one of the most important comorbidities in patients with chronic heart failure (HF) and frequently accentuated in the setting of acute HF (AHF). Serum creatinine and blood urea nitrogen (BUN) have been classically used as markers of renal dysfunction, despite having several limitations. High (BUN)/creatinine ratio has been associated with higher mortality in patients with HF. We aimed to predict the long-term outcome of patients admitted with acute heart failure to the emergency department using renal markers.
Methods
900 patients admitted to our emergency department diagnosed with AHF were retrospectively analysed. Patients were divided into 4 groups according to BUN and SCr on admission:
– BUN ≤33 mg/dL and SCr ≤1.56 mg/dL (group LowBUN/LowCr), n=544;
– BUN ≤33 mg/dL and SCr >1.56 mg/dl (group LowBUN/HighCr), n=25;
– BUN >33 mg/dL and SCr ≤1.56 mg/dL (group HighBUN/LowCr), n=131;
– BUN >33 mg/dL and SCr >1.56 mg/dL (group HighBUN/HighCr), n=200;
The primary end-point of this study was the occurrence of all-cause mortality during follow-up.
Results
The median (IQR) BUN level on admission was 28.0 (20) mg/dL, median (IQR) SCr level on admission was 1.15 (0.73) mg/d, mean age was 81±7 years, 50.8% (n=457) were women and median follow up was 7 months. A total of 41.2% patients were diabetic, 21.7% had at least mild COPD, CAD was present in 28.9% of cases, 44.0% had valvular heart disease and 68.4% patients had atrial fibrillation.
Creatinine, BUN and Cr/BUN ratio predicted survival at 6 months (p<0.05).
Survival was the lowest in the group HighBUN/HighCr and the highest in the group LowBUN/LowCr. As expected, BUN/Cr ratio was the highest in group HighBUN/LowCr and the lowest in group LowBUN/HighCr.
Conclusions
Despite not having the highest BUN/Cr ratio, patients with BUN >33 mg/dL and SCr >1.56 mg/dL showed the worst prognosis.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - S Martinho
- University Hospitals of Coimbra , Coimbra , Portugal
| | - G Campos
- University Hospitals of Coimbra , Coimbra , Portugal
| | - P Alves
- University Hospitals of Coimbra , Coimbra , Portugal
| | - J Rosa
- University Hospitals of Coimbra , Coimbra , Portugal
| | - M Ferreira
- University Hospitals of Coimbra , Coimbra , Portugal
| | - L Goncalves
- University Hospitals of Coimbra , Coimbra , Portugal
| |
Collapse
|
2
|
De Almeida JPL, Martinho S, Rosa J, Campos G, Cunha M, Ferreira M, Costa C, Marinho V, Goncalves L. Does my TAVR patient have cardiac amyloidosis? Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Aortic stenosis (AS) is highly age-related, and its prevalence is increasing rapidly in high-income countries. There are 2 major types of amyloid protein responsible for cardiac amyloidosis (CA) - transthyretin (TTR) and immunoglobulin lightchain (AL). Previous cohorts report an incidence ranging from 9 to 16% for the presence of CA in patients with AS referred for TAVR. These patients appear to have a similar prognosis to those with lone AS when undergoing TAVR, but a trend toward worse prognosis if left treated. We aimed to investigate the prevalence of CA in patients with severe AS referred for TAVR in the Portuguese population.
Methods
We prospectively recruited 60 consecutive patients referred for TAVR at our tertiary center between November 2020 and May 2021. 59 patients agreed to participate and signed an informed consent, approved by the local Ethics Commission. All patients performed coronary angiogram, echocardiogram, thoracic abdominal pelvic CT scan, ECG, bone scintigraphy (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid [DPD]) and blood and urine monoclonal immunoglobulin testing. (Figure 1).
Results
About half (54.2%) of patients were male, average age was 82 years and the prevalence of ischemic heart disease and cardiovascular risk factors was high. About one third of patients had atrial fibrillation and 27.1% were pacemaker carriers. Echocardiographic baseline findings were: maximum aortic valve gradient 72.77±18.18 mmHg; mean aortic valve gradient 43.49±11.60; aortic valve area 0.65±0.15 cm2; interventricular septum thickness 1.30±0.23 cm; left ventricular ejection fraction (LVEF) 52.06±11.35%; E/E' 14.63±7.5; tricuspid annular plane systolic excursion 19.2±4mm; right ventricle/ right atrial gradient 38.1±14.32mmHg.
CA was diagnosed in 6 (10.2%) patients. Perugini grade was 1 (n=3) and 3 (n=3). One patient (Perugini grade = 3) was found to have plasma cell dyscrasia, producing monoclonal IgG Kappa protein. CA patients were all male, older (86.5 vs 81.30 years, p=0.049), more frequently pacemaker carriers (66.7 vs 22.6%, p=0.041) and had a tendency to have a thicker interventricular septum (1.48 vs 1.28 cm, p=0.065).
Conclusions
We show that in the Portuguese population, the prevalence of CA in severe AS patients referred for TAVI is in line with what is observed in other countries. This has important consequences regarding the diagnosis and management of these patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - S Martinho
- University Hospitals of Coimbra , Coimbra , Portugal
| | - J Rosa
- University Hospitals of Coimbra , Coimbra , Portugal
| | - G Campos
- University Hospitals of Coimbra , Coimbra , Portugal
| | - M Cunha
- University Hospitals of Coimbra , Coimbra , Portugal
| | - M Ferreira
- University Hospitals of Coimbra , Coimbra , Portugal
| | - C Costa
- University Hospitals of Coimbra , Coimbra , Portugal
| | - V Marinho
- University Hospitals of Coimbra , Coimbra , Portugal
| | - L Goncalves
- University Hospitals of Coimbra , Coimbra , Portugal
| |
Collapse
|
3
|
De Almeida JPL, Martinho S, Girao A, Barreiro I, Baptista R, Ferreira J, Goncalves V, Milner J, Ferreira C, Alves P, Azul A, Goncalves L. P4751Underdosing fragile patients - Are we helping or harming? Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
An individualized approach should be taken regarding the utilization of direct oral anticoagulants (DOAC) in frail and elderly populations with atrial fibrillation (AF). We hypothesized that among an elderly and frail population, where the risk of bleeding, both real and perceived, is very high, the proportion of patients with a dose regimen different from the formal indication would be particularly high due to potential underdosing.
Methods
We conducted a retrospective, observational study enrolling 327 patients with AF admitted to an Internal Medicine ward during a 1-year period and discharged with a DOAC prescription. We divided the population in 2 groups: patients prescribed a reduced dose without formal dose reduction criteria (underdosed, n=170) and the rest of the population (n=157), which included adequately dosed patients, both with normal dose (n=99) and correctly reduced dose (n=43) and overdosed patients (n=15). A 1-year follow-up was completed for all patients, assessing the following outcomes: all-cause mortality, stroke, systemic embolism and major bleeding.
Results
Patients were elderly (81.9±7.68) and frail (Katz index 3.35±2.36). Apixaban was the most commonly prescribed NOAC (38.8%), followed by rivaroxaban (36.4%) and dabigatran (24.8%). Among underdosed patients, apixaban was prescribed in 45.3% of patients, dabigatran in 29.4% and rivaroxaban 25.3%. Although only 18.3% of patients had clinical criteria for dose reduction, 65.4% were discharged with reduced dose and thus 52% were underdosed.
Regarding 1-year outcomes, mortality (40.8% vs 25.5%, RR=1.6, p=0.003) and the combined stroke, systemic embolism and major bleeding event rate (10.1% vs 3.2%, RR=3.16, p=0.015) were higher for underdosed patients.
Among underdosed patients, comparing with the rest of the population, the increased ischemic events rate (ischemic stroke and systemic embolism) did not reached statistical significance (3.7% vs. 1.9%, p=0.5), but it did for hemorrhagic events (major bleeding and hemorrhagic stroke) (6.1% vs 0.6%, p=0.01)
On multivariate analysis, even after considering adjustment for age, Katz and CHAD2VAS2C scores, renal function and DOAC prescribed, DOAC underdosing was associated with a higher risk of both ischemic and hemorrhagic events (HR = 3.51, 95% CI 1.08–11.38). However, it lost its independent negative effect regarding mortality (HR 1.32, 95% CI 0.87–1.99).
Survival and event rate in underdosed
Conclusions
There is a significant proportion of frail and elderly patients with AF that are underdosed. This subset has a significant survival disadvantage, eventually reflecting prescription bias. However, underdosed patients have also a higher event rate of both ischemic and hemorrhagic events, suggesting that underdosing fragile patients is not an effective strategy and that instead it may be hazardous.
Collapse
Affiliation(s)
| | - S Martinho
- University Hospitals of Coimbra, Coimbra, Portugal
| | - A Girao
- University Hospitals of Coimbra, Coimbra, Portugal
| | - I Barreiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Coimbra, Portugal
| | - J Ferreira
- University Hospitals of Coimbra, Coimbra, Portugal
| | - V Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Coimbra, Portugal
| | - A Azul
- University Hospitals of Coimbra, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| |
Collapse
|